Bloomberg News reporter John Lauerman volunteered to have his DNA sequenced by Harvard researchers to demystify the process for the public. What he didn’t expect to uncover was that he possessed two gene variants–one linked to rare blood disorders and the other to a higher risk of Alzheimer’s.
Reporting in Science, researchers write that an FDA-approved drug for skin cancer had surprising results in mice with Alzheimer’s. The drug rapidly cleared up amyloid protein from the brain and improved cognitive function. Co-author Gary Landreth discusses the drug’s potential as a therapy for Alzheimer’s.